Imugene’s ‘holy grail’ cancer therapy taken to USA
SYDNEY: ASX-listed immuno-oncology company Imugene has penned a licensing patent deal with the California-based cancer
SYDNEY: ASX-listed immuno-oncology company Imugene has penned a licensing patent deal with the California-based cancer